Cidara Therapeutics has announced the expansion of its existing collaboration with WuXi XDC for advancing the CD73 oncology DFC programme.

The deal builds on the existing partnership with WuXi XDC for chemistry, manufacturing, and controls (CMC) development and GMP manufacturing services for the CD388 influenza drug-Fc conjugate (DFC) programme of Cidara.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the latest deal, WuXi XDC will be responsible for providing investigational new drug (IND)-enabling CMC development services for Cidara’s lead CD73 oncology DFC programme.

Cidara Therapeutics president and CEO Jeff Stein said: “WuXi XDC has been an excellent development and manufacturing partner for our ongoing CD388 influenza DFC programme, and we are excited to expand this relationship by combining WuXi XDC’s core competencies in bioconjugates manufacturing with our expertise in DFCs to advance the manufacturing of our first-in-class CD73 oncology DFC.”

CD421, the company’s lead oncology candidate, works by targeting CD73 in the adenosine pathway that contributes to immune evasion in solid cancers.

Cidara stated that CD73 is extremely expressed on many tumour and stromal cells and immunosuppressive cells, including myeloid-derived suppressor cells and regulatory T cells.

The CD73 DFC has been designed for addressing the pharmacokinetic, safety, efficacy, and potency limitations of small molecule and monoclonal antibody candidates that target CD73.

WuXi XDC CEO Dr Jimmy Li said: “This expanded partnership is a strong testament to our industry-leading capabilities and expertise.

“We’re committed to building an innovation ecosystem for bioconjugates by offering global open-access technology platforms with premier quality standards to support our partners worldwide as they build their innovative ideas into transformative new treatments for patients.”